Life Biosciences has appointed David Guyer, M.D., to its board of directors, according to the company. The appointment is intended to strengthen the company’s leadership as it advances its research and development programs focused on extending healthy lifespan through cellular rejuvenation technologies.
According to the company, Dr. Guyer brings extensive experience in biotechnology and ophthalmology, having co-founded and led multiple life sciences companies. Life Biosciences said his expertise in clinical development, strategic growth, and corporate governance will support the company’s efforts to progress its therapeutic pipeline targeting aging-related decline.
The company said it is currently developing therapies designed to restore cellular health and resilience, with the goal of addressing age-associated diseases and conditions. It claims that its scientific approach focuses on reprogramming the body’s cellular mechanisms to promote regeneration and improve overall function.
Life Biosciences stated that Dr. Guyer’s appointment reflects its commitment to building a leadership team capable of guiding the company through the next stages of clinical and commercial development. The company said that his addition to the board will play a role in shaping its long-term strategy within the growing longevity biotechnology sector.
